LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

SIGA Technologies Inc

Затворен

СекторЗдравеопазване

6.76 1.35

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.76

Максимум

6.83

Ключови измерители

By Trading Economics

Приходи

-42M

-6.4M

Продажби

-79M

2.6M

P/E

Средно за сектора

6.34

121.746

EPS

-0.089

Марж на печалбата

-242.97

Служители

46

EBITDA

-56M

-8.2M

Дивиденти

By Dow Jones

Следващи печалби

10.03.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-120M

468M

Предишно отваряне

5.41

Предишно затваряне

6.76

Настроения в новините

By Acuity

50%

50%

127 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

SIGA Technologies Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.02.2026 г., 23:21 ч. UTC

Придобивния, сливания и поглъщания

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15.02.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Falls on Possible Position Adjustments -- Market Talk

15.02.2026 г., 23:06 ч. UTC

Печалби

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15.02.2026 г., 23:04 ч. UTC

Печалби

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15.02.2026 г., 23:04 ч. UTC

Печалби

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15.02.2026 г., 23:01 ч. UTC

Печалби

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15.02.2026 г., 23:01 ч. UTC

Печалби

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15.02.2026 г., 22:52 ч. UTC

Придобивния, сливания и поглъщания

Qube Shareholders to Receive A$5.20/Share in Cash

15.02.2026 г., 22:52 ч. UTC

Придобивния, сливания и поглъщания

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO Tania Archibald Speaking on a Call With Media

15.02.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15.02.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15.02.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15.02.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15.02.2026 г., 20:48 ч. UTC

Печалби

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15.02.2026 г., 20:47 ч. UTC

Печалби

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15.02.2026 г., 20:46 ч. UTC

Печалби

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15.02.2026 г., 20:45 ч. UTC

Печалби

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15.02.2026 г., 20:44 ч. UTC

Печалби

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15.02.2026 г., 20:44 ч. UTC

Печалби

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15.02.2026 г., 20:43 ч. UTC

Печалби

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15.02.2026 г., 20:42 ч. UTC

Печалби

BlueScope Net Debt A$2.2 Million at Dec. 31

15.02.2026 г., 20:42 ч. UTC

Печалби

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15.02.2026 г., 20:41 ч. UTC

Печалби

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15.02.2026 г., 20:40 ч. UTC

Печалби

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15.02.2026 г., 20:40 ч. UTC

Печалби

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15.02.2026 г., 20:39 ч. UTC

Печалби

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Сравнение с други в отрасъла

Ценова промяна

SIGA Technologies Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

0

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

5.41 / 5.63Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

127 / 351 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно SIGA Technologies Inc

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
help-icon Live chat